DrugInformer Search


Ingredients: Aprotinin
Average User Review Score
* Based on 4 reviews from across the web.

The drug aprotinin (Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is the small protein bovine pancreatic trypsin inhibitor (BPTI), an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.

Read more on Wikipedia

  Please use Workbench for in-depth research on Trasylol.

* Extracted from FDA Adverse Event Reports for all drugs with the same active ingredients.

Tell us about your Experience with Trasylol

Thank you for sharing your experience with us!

Share Your Experience

Druginformer Identified Side Effects: Sudden death

Posted By Anonymous in fdb.rxlist.com on May 12, 2009 @ 12:00 am

My father had open heart surgery on June 4,2008 and never made it out of recovery. He passed away on August 15,2008.

Druginformer Identified Side Effects: None

Posted By Anonymous in fdb.rxlist.com on May 25, 2008 @ 12:00 am

Rec'd from HSI e-Alert 5/22/08 TRASYLOL used to control bleeding in Surg.has been associated with up to 1000 DEATHS a Month since introduced 14 yrs. ago ?? No record in Snopes? Comment ? jwbrown26@h...

Druginformer Identified Side Effects: Anaemia, Renal failure, Atrial fibrillation, Cardiac failure congestive

Posted By Anonymous in askapatient.com on July 26, 2007 @ 12:00 am

Side Effects: kidney failure requiring dialysis 3 days a week, arterial fibrillation, anemia, and congestive heart failure My daddy was given trasylol after his heart bypass surgery and now...

Druginformer Identified Side Effects: Renal failure, Myocardial infarction, Cerebrovascular accident, Cardiac failure

Posted By Anonymous in askapatient.com on June 30, 2006 @ 12:00 am

Side Effects: The New England Journal of Medicine recently found the use of Trasylol doubled the risk of kidney failure, increased the chance of heart attack or heart failure by 55% and resulted in a...

Druginformer Identified Side Effects: None

Posted By Anonymous in facebook.com on August 15, 2009 @ 12:00 am

Gloria http://www.makewave/ snow.com/ dangerous- drugs/?AFID= 59937&SID=EZBDanDru200908 13j1nm " Have You or a Loved One Been Injured or Killed By a Dangerous Drug? Adverse reactions from prescription...

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.